Modulation of uridine phosphorylase gene expression by tumor necrosis factor-α enhances the antiproliferative activity of the capecitabine intermediate 5′-deoxy-5-fluorouridine in breast cancer cells

Molecular Pharmacology

Volumn 69, Issue 4, 2006, Pages 1389-1395

  Wan, Laxiang ^a   Cao, Deliang ^b   Zeng, Jianmin ^a   Yan, Ruilan ^b   Pizzorno, Giuseppe ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CAPECITABINE; DOXIFLURIDINE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; URIDINE PHOSPHORYLASE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; DEOXYCYTIDINE; DNA PRIMERS; DRUG SYNERGISM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOXURIDINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA; URIDINE PHOSPHORYLASE;

EID: 33645100552     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.018515     Document Type: Article

References (39)

1. Armstrong RD, Connolly KM, Kaplan AM, and Cadman E (1983) Mechanism of cytotoxic activity of 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 11:102-105.
2. Blum JL (1999) Xeloda in the treatment of metastatic breast cancer. Oncology 57:16-20.
3. Cao D, Leffert JJ, McCabe J, Kim B, and Pizzorno G (2005) Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J Biol Chem 280:21169-21175.
4. Cao D, Nimmakayalu MA, Wang F, Zhang D, Handschumacher RE, Bray-Ward P, and Pizzorno G (1999) Genomic structure, chromosomal mapping and promoter region analysis of murine uridine phosphorylase gene. Cancer Res 59:4997-5001.
5. Cao D and Pizzorno G (2004) Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today 40:431-443.
6. Cao D, Russell RL, Zhang D, Leffert JJ, and Pizzorno G (2002) Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 62:2313-2317.
7. Eda H, Fujimoto K, Watanabe S, Ishikawa T, Ohiwa T, Tatsuno K, Tanaka Y, and Ishitsuka H (1993) Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5- fluorouridine. Jpn J Cancer Res 84:341-347.
8. Goto H, Kohno K, Sone S, Akiyama S, Kuwano M, and Ono M (2001) Interferon gamma-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through gamma-activated sequence-like element in human macrophages. Cancer Res 61:469-473.
9. Han Y and Brasier AR (1997) Mechanism for biphasic rel A. NF-κB1 nuclear translocation in tumor necrosis factor α-stimulated hepatocytes. J Biol Chem 272:9825-9832.
10. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, et al. (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292.
11. Hoffmann A, Levchenko A, Scott ML, and Baltimore D (2002) The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science (Wash DC) 298:1241-1245.
12. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, and Ishitsuka H (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097.
13. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, and Maruyama HB (1980) Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 71:112-123.
14. Kanzaki A, Takebayashi Y, Bando H, Eliason JF, Watanabe Si S, Miyashita H, Fukumoto M, Toi M, and Uchida T (2002) Expression of uridine and thymidine phosphorylase genes in human breast carcinoma. Int J Cancer 97:631-635.
15. Katsumata K, Tomioka H, Sumi T, Yamashita S, Takagi M, Kato F, Nakamura R, Koyanagi Y, Aoki T, and Kato K (2003) Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens. Cancer Chemother Pharmacol 51:155-160.
16. Kufe DW and Major PP (1981) 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 256:9802-9805.
17. Leong KG and Karsan A (2000) Signaling pathways mediated by tumor necrosis factor alpha. Histol Histopathol 15:1303-1325.
18. Leyva A, Kraal I, Lankelma J, Delemarre JF, and Pinedo HM (1983) High uridine phosphorylase activity in human melanoma tumor. Anticancer Res 3:227-231.
19. Lin ZP, Boller YC, Amer SM, Russell RL, Pacelli KA, Patierno SR, and Kennedy KA (1998) Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance. Cancer Res 58:3059-3065.
20. Liu M, Cao D, Russell R, Handschumacher RE, and Pizzorno G (1998) Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res 58:5418-5424.
21. Longley DB, Harkin DP, and Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338.
22. Maehara Y, Moriguchi S, Emi Y, Watanabe A, Kohnoe S, Tsujitani S, and Sugimachi K (1990) Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas. Cancer 66:156-161.
23. Major PP, Egan E, Herrick D, and Kufe DW (1982) 5-Fluorouracil incorporation in DNA of human breast carcinoma cells. Cancer Res 42:3005-3009.
24. Martin DS, Stolfi RL, and Sawyer RC (1989) Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 24:9-14.
25. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, and Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281.
26. Miyashita H, Takebayashi Y, Eliason JF, Fujimori F, Nitta Y, Sato A, Morikawa H, Ohashi A, Motegi K, Fukumoto M, et al. (2002) Uridine phosphorylase is a potential prognostic factor in patients with oral squamous cell carcinoma. Cancer 94:2959-2966.
27. Peters GJ (1988) Preclinical and clinical biochemical modulation of 5-fluorouracil by leucovorin and uridine. Sci Rep Res Inst Tohoku Univ Ser C Med 35:15-17.
28. Pizzorno G, Cao D, Leffert JJ, Russell RL, Zhang D, and Handschumacher RE (2002) Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta 1587:133-144.
29. Saeki T, Tanada M, Takashima S, Saeki H, Takiyama W, Nishimoto N, and Moriwaki S (1997) Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas. Jpn J Clin Oncol 27:227-230.
30. Schilsky RL (2000) Pharmacology and clinical status of capecitabine. Oncology (Williston Park) 14:1297-12306.
31. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, and Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297.
32. Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, and Sawyer R (1993) Uridine allows dose escalation of 5-fluorouracil when given with Nphosphonacetyl-L-aspartate, methotrexate, and leucovorin. Cancer 71:1875-1881.
33. Shimabukuro T, Matsuyama H, Baba Y, Jojima K, Suyama K, Aoki A, Suga A, Yamamoto N, and Naito K (2005) Expression of thymidine phosphorylase in human superficial bladder cancer. Int J Urol 12:29-34.
34. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, and Van Waes C (2001) Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7:1419-1428.
35. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, et al. (2001) Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106.
36. Watanabe S, Hino A, Wada K, Eliason JF, and Uchida T (1995) Purification, cloning and expression of murine uridine phosphorylase. J Biol Chem 270:12191-12196.
37. Yang Q, Barbareschi M, Mori I, Mauri F, Muscara M, Nakamura M, Nakamura Y, Yoshimura G, Sakurai T, Caffo O, et al. (2002) Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int J Cancer 97:512-517.
38. Zhang D, Cao D, Russell R, and Pizzorno G (2001) p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction. Cancer Res 61:6899-6905.
39. Zhu GH, Lenzi M, and Schwartz EL (2002) The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells. Oncogene 21:8477-8485.